Literature DB >> 32986381

LTA, LEP, and TNF-a Gene Polymorphisms are Associated with Susceptibility and Overall Survival of Diffuse Large B-Cell lymphoma in an Arab Population: A Case-Control Study.

Sohaib M Al-Khatib1, Nour Abdo2, Laith N Al-Eitan3, Abdel-Hameed W Al-Mistarehi4, Deeb Jamil Zahran5, Tariq Zuheir Kewan5,6.   

Abstract

OBJECTIVE: In this study, we aimed to explore the relationship between five selected proinflammatory and immune-mediated genes (TNF rs1800629G>A, rs361525G>A, rs1799964T>C, LTA rs1800683G>A, rs909253A>G, TNFAIP8 rs1042541C>T, LEPR rs1327118G>C, and LEP rs2167270G>A) and the risk and overall survival of DLBCL patients within the Jordanian Arab population.
METHODS: One hundred twenty-five patients (125) diagnosed with DLBCL at the King Abdullah University Hospital (KAUH) between 2013 and 2018 and 238 healthy cancer-free control subjects with similar geographic and ethnic backgrounds to the patients were included in the study. Genomic DNA was extracted from the formalin-fixed paraffin-embedded tissues of the subjects and from peripheral blood samples of the controls. The Sequenom MassARRAY® sequencer system (iPLEX GOLD) was used. The analyses included assessments of population variability and survival.
RESULTS: Our study showed significant differences in the distribution of the studied polymorphisms of DLBCL between the patients and controls for TNF rs1800629G>A, LTA rs909253 G>A and LEP rs2167270 G>A. TNF rs1800629G>A (p = 0.01), in which the G allele harbors a higher risk of DLBCL (GG and GA genotypes when compared with AA genotype) (p = 0.044). The LTA rs909253 A>G polymorphism is associated with a higher risk of DLBCL in the allelic model (p = .004).  LEP rs2167270 G>A polymorphism is associated with a decreased risk of DLBCL in the recessive mode models (p = .03). Subjects with the dominant model for TNF-a rs1799964 (TT genotype in comparison with the combined TT/TC genotype) and patients with the homozygous genotype (GG) of rs361525 have better overall survival rates.
CONCLUSION: Our results confirmed the diversity and the heterogeneity of the disease. Although the study has a limitation because of its relatively small size, it clearly emphasizes the significance of ancestry and genetic composition as the determinants of DLBCL risk and behavior.<br />.

Entities:  

Keywords:  Arab population; Diffuse large B-cell lymphoma; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32986381      PMCID: PMC7779465          DOI: 10.31557/APJCP.2020.21.9.2783

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  65 in total

1.  The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma.

Authors:  Mattias Berglund; Ulf Thunberg; Göran Roos; Richard Rosenquist; Gunilla Enblad
Journal:  Blood       Date:  2005-06-15       Impact factor: 22.113

2.  Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response.

Authors:  S Patel; F H Wang; T L Whiteside; U Kasid
Journal:  Oral Oncol       Date:  1997-05       Impact factor: 5.337

3.  Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2.

Authors:  Arianne L Theiss; James G Simmons; Christian Jobin; P Kay Lund
Journal:  J Biol Chem       Date:  2005-09-01       Impact factor: 5.157

4.  Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer.

Authors:  Qian-Ze Dong; Yue Zhao; Yang Liu; Yang Wang; Peng-Xin Zhang; Gui-Yang Jiang; Xin-Jun Dong; Quan-Ze Cui; En-Hua Wang
Journal:  Cancer Sci       Date:  2010-03-10       Impact factor: 6.716

5.  TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma.

Authors:  Yuni Elsa Hadisaputri; Tatsuya Miyazaki; Shigemasa Suzuki; Takehiko Yokobori; Tsutomu Kobayashi; Naritaka Tanaka; Takanori Inose; Makoto Sohda; Hiroyuki Kuwano
Journal:  Ann Surg Oncol       Date:  2011-10-04       Impact factor: 5.344

6.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Hematol J       Date:  2000

7.  Dietary factors and non-Hodgkin's lymphoma: a case-control study in the northeastern part of Italy.

Authors:  S Franceschi; D Serraino; A Carbone; R Talamini; C La Vecchia
Journal:  Nutr Cancer       Date:  1989       Impact factor: 2.900

8.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation.

Authors:  H Hsu; J Xiong; D V Goeddel
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

Review 9.  LEP and LEPR polymorphisms in non-Hodgkin lymphoma risk: a systematic review and pooled analysis.

Authors:  Hai-Yan Lin; Hui Shi; Chun-Yan Li; Quan-Chi Chen; Tian-Bao Huang; Peng-Cheng Liu; Lie-ming Lou
Journal:  J BUON       Date:  2015 Jan-Feb       Impact factor: 2.533

10.  Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms.

Authors:  E V Willett; C F Skibola; P Adamson; D R Skibola; G J Morgan; M T Smith; E Roman
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

View more
  2 in total

Review 1.  Susceptibility of TNFAIP8, TNFAIP8L1, and TNFAIP2 Gene Polymorphisms on Cancer Risk: A Comprehensive Review and Meta-Analysis of Case-Control Studies.

Authors:  Khokon Kanti Bhowmik; Md Abdul Barek; Md Abdul Aziz; Mohammad Safiqul Islam
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in the Risk of Cancer: A Meta-Analysis.

Authors:  Aiqiao Zhang; Shangren Wang; Fujun Zhang; Wei Li; Qian Li; Xiaoqiang Liu
Journal:  Front Oncol       Date:  2021-11-18       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.